Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 9/20 | 0.79 |
| ▸ | ORAI1 | Q96D31 | 9/20 | 0.79 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.39 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.39 |
| ▸ | GPR55 | Q9Y2T6 | 1/20 | 0.36 |
| ▸ | EIF2AK1 | Q9BQI3 | 1/20 | 0.36 |
| ▸ | GCGR | P47871 | 1/20 | 0.35 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | SCN1A | P35498 | 1/20 | 0.35 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.35 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14150230 | 0.88 | STIM1 (1.00) | STIM1ORAI1ORAI2CNR2GABRA5 | |
| SCHEMBL15258916 | 0.84 | STIM1 (0.84) | STIM1ORAI1ORAI2CNR2GABRA5 | |
| SCHEMBL14226015 | 0.84 | STIM1 (0.86) | STIM1ORAI1ORAI2CNR2GABRA5 | |
| SCHEMBL14226010 | 0.83 | STIM1 (1.00) | STIM1ORAI1 | |
| SCHEMBL14150207 | 0.83 | STIM1 (0.72) | STIM1ORAI1ORAI2CNR2HDAC3 | |
| SCHEMBL14225957 | 0.82 | STIM1 (0.65) | STIM1ORAI1ORAI2CNR2GPR55 | |
| SCHEMBL14225944 | 0.82 | STIM1 (0.70) | STIM1ORAI1ORAI2CNR2GPR55 | |
| SCHEMBL14150223 | 0.82 | STIM1 (1.00) | STIM1ORAI1ORAI2GABRA5GPR55 | |
| SCHEMBL14150267 | 0.81 | STIM1 (0.79) | STIM1ORAI1ORAI2CNR2GPR55 | |
| SCHEMBL14226013 | 0.80 | STIM1 (0.68) | STIM1ORAI1ORAI2CNR2GPR55 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | AVENUE CAPITAL MANAGEMENT II, L.P. | 2016-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160304502-A1 | COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM | ORAI1, SARAF, RYR2 | STIM1 17/4885ORAI1 1/4885ORAI2 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.